SCHEMBL7230378

SCHEMBL7230378

CS(=O)(=O)NCc1ccc(CO)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.65
KDM4E B2RXH2 1/20 0.54
POLB P06746 1/20 0.54
TSHR P16473 1/20 0.54
RECQL P46063 1/20 0.54
NAMPT P43490 1/20 0.46
CA2 P00918 6/20 0.45
CA1 P00915 5/20 0.45
CA12 O43570 3/20 0.45
CA7 P43166 2/20 0.45
CA14 Q9ULX7 2/20 0.45
CA9 Q16790 2/20 0.45
CA4 P22748 1/20 0.45
CA6 P23280 1/20 0.45
CA5A P35218 1/20 0.45
CA5B Q9Y2D0 1/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CNR2 P34972 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3605085 0.83 KMT2A (0.65) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL8062129 0.82 CA1 (0.56) KMT2AKDM4ETSHRCA2CA1
SCHEMBL7230521 0.82 KMT2A (0.46) KMT2AKDM4ECA2CA1CA12
SCHEMBL4491485 0.81 KMT2A (0.61) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL14852 0.81 KMT2A (0.61) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL3605081 0.81 KMT2A (0.61) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL5314524 0.79 KMT2A (0.59) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL552189 0.79 KMT2A (0.59) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL6338974 0.79 KMT2A (0.70) KMT2AKDM4EPOLBTSHRRECQL
SCHEMBL22497546 0.79 KMT2A (0.59) KMT2AKDM4EPOLBTSHRRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6645989-B2 Antiinflammatory agents SMITHKLINE BEECHAM CORPORATION 2003-11-11 US disclosed
US-20030064997-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION 2003-04-03 US disclosed
US-6268370-B1 CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION 2001-07-31 US disclosed
US-5916891-A CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1999-06-29 US disclosed
US-5686455-A Imidazole derivatives and their use as cytokine inhibitors SMITHKLINE BEECHAM CORPORATION (US) 1997-11-11 US disclosed
US-5656644-A CYTOKINE SUPPRESSORS SMITHKLINE BEECHAM CORPORATION (US) 1997-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064997-A1 Novel compounds BRD4, BRDT, HDAC6 KMT2A 2124/4885KDM4E 2100/4885POLB 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.